دورية أكاديمية
Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.
| العنوان: | Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. |
|---|---|
| المؤلفون: | Long AH; Division of Hematology, Oncology, and Stem Cell Transplant, Department of Pediatrics, Stanford University, Stanford, CA., Morgenstern DA; Division of Haematology/Oncology, Department of Paediatrics, Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada., Leruste A; SIREDO Oncology Center, Institut Curie, Paris Sciences et Lettres University, Paris, France., Bourdeaut F; SIREDO Oncology Center, Institut Curie, Laboratory of Translational Research in Pediatric Oncology, Paris, France., Davis KL; Division of Hematology, Oncology, and Stem Cell Transplant, Department of Pediatrics, Stanford University, Stanford, CA.; Center for Cancer Cellular Therapy, Stanford University, Stanford, CA. |
| المصدر: | American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting [Am Soc Clin Oncol Educ Book] 2022 Apr; Vol. 42, pp. 1-14. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101233985 Publication Model: Print Cited Medium: Internet ISSN: 1548-8756 (Electronic) Linking ISSN: 15488748 NLM ISO Abbreviation: Am Soc Clin Oncol Educ Book Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Alexandria, Va. : American Society of Clinical Oncology |
| مواضيع طبية MeSH: | Hodgkin Disease* , Pediatrics*, Child ; Humans ; Immune Checkpoint Inhibitors ; Immunologic Factors ; Immunotherapy |
| مستخلص: | The role of immune checkpoint inhibitors (ICIs) in the treatment of pediatric cancers continues to evolve. Such therapies function by augmenting existing antitumor T-cell responses that have been rendered ineffective by inhibitory pathways. Although ICIs have proven highly effective for adult cancers, initial phase I/II clinical trials using single-agent ICIs against unselected pediatric cancers have been overall disappointing. With the exception of pediatric classic Hodgkin lymphoma, responses to ICIs have been infrequent, likely stemming from an inherent difference in the immunogenicity of childhood cancers, which, on average, have far fewer neoantigens than adult cancers. Recently, however, hope has reemerged that certain subsets of children with cancer may benefit from ICI therapies. In preliminary studies, patients with both pediatric hypermutated and SMARCB1-deficient cancers have had impressive responses to ICI therapies, likely as a result of underlying biologies that enhance neoantigen expression and tumoral inflammation. Dedicated trials are ongoing to fully evaluate the efficacy of ICIs for patients with these subsets of pediatric cancer. |
| المشرفين على المادة: | 0 (Immune Checkpoint Inhibitors) 0 (Immunologic Factors) |
| تواريخ الأحداث: | Date Created: 20220517 Date Completed: 20220519 Latest Revision: 20220519 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1200/EDBK_349799 |
| PMID: | 35580293 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1548-8756 |
|---|---|
| DOI: | 10.1200/EDBK_349799 |